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Appendix 1. 
SRDC Thematic Research Programme, 2020 - 2022 
Title: ‘Waging War Against Anti-microbial Resistance’ 
  
Aim: To develop and advance research programme in anti-microbial resistant and discovery of 
new anti-microbials against clinically relevant pathogens  
 
Objectives 
1. To elucidate the molecular mechanisms and cellular biology of anti-microbial resistance using 
systems biology approaches 
2. To identify and validate new druggable targets for existing and novel anti-microbials 
3. To establish in depth understanding on the complex dynamic interactions between host, 
pathogens and environment on anti-microbial resistance status, evolution and transmission 
4. To accelerate therapeutic discovery and establish pipeline for next generation anti-microbial 
development 
Target infectious agent: 
a. Bacteria of clinical relevance - Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. 




Problem Statement: Antimicrobials have been used as effective therapy for community 
associated infections with mild level of bacteria resistance. However, due to extensive and 
uncontrolled use of antibiotics over the past decades, an alarming trend of antibiotic resistance 
developed among clinically-important bacteria.1,2 Consequently, the treatment options for many 
infections are dwindling and worryingly limited. Antimicrobial resistance (AMR) is a serious 
emerging global threat. AMR is one of the biggest threats to global health, food security, and 
development to date. A recent review by Jim O’Neill projected that the annual death toll caused 
AMR could reach 10 million by the year 2050 if no actions were taken to address the issue.3 In 
the United States of America, according to a CDC report, at least 2 million Americans are 
infected with drug resistant pathogens annually and at least 23,000 of them die from such 
infection.4 In Malaysia, the National Surveillance of Antibiotic Resistance 2017 reported similar 
trend with antibiotic resistance reported to be increasing for Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp. Combined, for which the acronym ‘ESKAPE’ was devised to 
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discuss them collectively, they are responsible for a significant global disease burden. Much of 
their associated morbidity and mortality is due to nosocomial emergence of AMR. Alarmingly in 
Malaysia is the increasing resistance of certain bacteria against the last line of therapeutic 
defence such as carbapenem-resistant Klebsiella pneumoniae with an increase from 0.3% in 
2011 to 2.8% in 2015.5 Such trend is not unique to just K. pneumoniae but in other pathogens 
such as increasing resistance of Enterococcus faecium and Enterococcus faecalis to linezolid.5 
AMR is not just isolated to bacterial infection, but that of other pathogenic infection such as 
soil transmitted helminthiasis. The WHO estimated that around 1.5 billion people around the 
world is infected with soil-transmitted helminth (STH) including Sarawak.6,7 The common STHs 
of clinical importnace are hookworm (Ancylostoma duodenale and Necator americanus), 
roundworm (Ascaris lumbricoides), and whipworm (Trichuris trichiura). However, there are 
various other STHs that causes various debilitating health conditions particularly in the rural 
communities and livestock industries. Soil-transmitted helminthiasis, taken as a whole, accounts 
for a global burden of over 3.3 million disability-adjusted life years8 associated with various 
health conditions such as anaemia,9  malnutrition,10 and impaired physical and cognitive 
development.11-13 Alarmingly, resistance to the limited number drugs available against STHs 











Figure 1. Dates of discovery of distinct classes of antibacterial drugs.15 
The issue on AMR is potentially catastrophic to global population leading WHO to list 
AMR as one of the top ten threats to global health in 2019. Adding to the urgency of the 
problem, current pipeline for development of new antimicrobials is effectively non-existent. 
Since the discovery of penicillin by Sir Alexander Fleming in 1928, the discovery of new 
antibiotics reached its peak in the 1950s and 60s (Figure 1).15 The last completely new class of 
Version 1  War on ID 
21st August 2019 
Dr. Ivan K. S. Yap, on behalf of the SRDC 
antibiotics were discovered in 1980s after which there was a discovery void which coincides 
with the global therapeutic shift towards combatting non-communicable diseases such as 
cancer and cardiovascular diseases. With ever increasing incidence of multi-drug resistant 
bacteria, common infections are getting more difficult to treat and are beginning to cause more 
severe infections presenting major threats to society. Incidence of community-acquired 
infections such as pneumonia, which traditionally is treated with penicillin, are getting less 
responsive to first line antibiotics. Cystitis, a common bacterial infection in women, is usually 
treated with oral antibiotics, now requiring treatments via other route of administration thus 
imposing more cost and increasing frequency of treatment failure. Common infections in 
hospital intensive care and neonatal units are increasingly becoming extremely difficult to treat 
and threatening the lives of patients.15 
 Thus, there is an urgent need for a concerted global effort to address this ever-increasing 
threat to the global population. The WHO initiated the Global Action Plan on Antimicrobial 
Resistance programme in response to the ever-increasing threat of AMR. The long-term goal 
of the programme is “… to ensure, for as long as possible, continuity of successful treatment 
and the prevention of infectious with effective and safe medicines that are quality assured, 
used in a responsible way, and accessible to all who need them.”16 As part of the SRDC initiative 
to address the current global need and the needs of Sarawak in tackling AMR, echoing the 
WHO Global Action Plan on Antimicrobial Resistance programme, the SRDC is initiating a 
targeted research programme tapping into the vast biodiversity of Sarawak aimed at antibiotic 
discovery, development, disease diagnostics and surveillance. The over-arching aim of this 
programme is to develop and advance research programme in anti-microbial resistant and 
discovery of new anti-microbials against clinically relevant pathogens tapping into the richness 
of Sarawak biodiversity. The SRDC has identified four key objectives which will drive the AMR 
programme. These objectives are set to promote collaboration between diverse disciplines, 
encourage sharing of information, skills and knowledge exchanges, and stimulate investments 
from the public and private sectors, which ultimately accelerate acquisition of new insights into 
the emergence and spread of antimicrobial resistance, the evolution of resistance and drive the 
discovery of new diagnostic, preventative and therapeutic strategies for microbial infections. 
This programme will also provide a real-life test bed for studying the impact of different 
economic and business models, or development of novel business models, related to the 
process and drivers of innovation in the development of new antibiotics and diagnostics.  
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Objectives: 
1. To elucidate the molecular mechanisms and cellular biology of anti-microbial 
resistance using systems biology approaches 
Description: A strong fundamental microbiology and in-depth understanding of microbial 
resistance from the genome, through to cellular and host pathogen interactions in laboratory 
environment will be established on the initial stage of the programme in order to provide 
better insights into fundamental mechanisms of resistance development. This will run 
concurrently with disease surveillance and epidemiology to update the current communicable 
disease prevalence in Sarawak. Such approach will enable development and testing of new 
models (in vitro and in vivo) for anti-microbial testing as well as functional screening on 
evolution of resistance utilising data generated from the surveillance study. This objective is 
expected to provide the fundamental knowledge to underpin many of the other activities in 




a. provide better understanding of resistant bacteria in the host context; 
b. define better ways of predicting and influencing the acquisition and evolution of 
resistance; and 
c. uncover new markers for diagnosing bacterial infection, virulence and resistance. 
 
2. To identify and validate new druggable targets for existing and novel anti-
microbials 
Description: Working across disciplines, the identification of new “druggable” anti-microbial 
targets through the application of structural, systems and synthetic biology will be 
accelerated. Bioinformatics, computational biology and mathematical modelling will facilitate 
systems-level approaches to better understand resistance mechanisms, their evolution and 
spread in human- and animal- bacterial pathogens, and drug design. Molecular level 
understanding of resistance mechanisms and antibacterial mechanisms of action will be 
investigated using advanced structural and imaging approaches through fostering links 




a. identify new targets for novel anti-microbial testing 
b. reveal new potential binding sites for existing treatment and structural modification 
(in silico and in vitro) to enhance binding affinity and drug effectiveness 
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3. To establish in depth understanding on the complex dynamic interactions 
between host, pathogens and environment on anti-microbial resistance status, 
evolution and transmission  
Description: The environment has been shown to interact with individuals and communities 
which subsequently influence the way microbes behave and response from the gene level 
within a microbe to the way resistant genes are transmitted between microbe species. Thus, 
in depth understanding on the effects of different environmental factors including 
antimicrobial selection pressure on evolution, acquisition and transmission of anti-microbial 
resistance must be established. Environmental factors stated here encompass host gut 
microbiota, hospital and care homes, transport systems, waste water treatment, agricultural 
practices and the natural environment. It is envisaged that by understanding the role of 
environmental factors on resistant formation and patterns, better preventive methods and 
management practices can be formulated.  
 Achieving this objective will require active close participation across different disciplines 
(medicine, life sciences, physical science and engineering) and agencies both from the public 




a. Greater understanding of how resistant bacteria adapt to their environments and vice 
versa; 
b. Understanding the dynamics of community interaction and how this affects resistance 
and transmission in community; 
c. Ways to manipulate environments to prevent resistance evolution and transmission; 
and 
d. New surveillance networks across different environments in collaboration with federal 
and state agencies 
 
4. To accelerate therapeutic discovery and establish pipeline for next generation 
anti-microbial development 
Description: This theme will cover the discovery of new and revisit old small molecule 
approaches as well as developing novel treatments utilising the vast biodiversity and natural 
product libraries in Sarawak. Building on discoveries in Objective 1 as well as on existing 
validated targets, elements of this objective will be directed towards strategies designed to 
exploit chemicals isolated from Sarawak biodiversity for the identification of novel small 
molecule antibiotics. This objective also covers development of new diagnostic technologies 
(from Objective 1) for early detection of resistant microbes as well as prognostic utility. In 
addition, this objective will look into establishing and accelerating anti-microbial discovery 
and development pipeline. New anti-microbials and existing drug repurposing will be studied 
using latest scientific findings and technology to improve efficacy and reduce resistant 
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tendency. Genome mining and metabolic pathway analysis for new synthetic pathways for 
antibiotics, bioengineering, synthetic biology, small molecule libraries with broader chemical 
space will be established and used. Further, other potential treatment or management 
modalities will be studied including but not limited to human vaccine development, passive 
immunotherapy, bacteriophage technology and probiotics. Long term study will include 
understanding functional genomics of the microbiome in order to manipulate and prevent 
evolution and spread of resistant strains. 
 
The research and development activities for this objective will also cover scale up and 
manufacture of novel antibiotic drugs and vaccine development technology in Sarawak. The 
interaction with private sector including biotech start-ups will be key to accelerate the 
translation of such new therapies. Development of next generation diagnostics through the 
integration of cutting-edge engineering and physical sciences with bacteriology could create 
simple, reliable, diagnostics for resistant bacteria in clinical and environmental settings. New 
diagnostics will also allow more targeted use of new antibacterial agents. Development of 
technological advances into new sensor systems will require partnership between industry 
and academia, and offers great opportunities for the private sector. Researchers should be 
mindful of the challenges associated with deploying new technologies in community settings, 
veterinary practices, care homes, farms etc. Such diagnostics may also form the basis of 
novel surveillance systems and this objective also includes development of new 




a. Establish and accelerate pipeline for antibiotic discovery and development including 
delivery systems; 
b. develop new non-drug-based treatments that can avoid resistance; 
c. develop rapid, point of care diagnostics for early detection and targetted therapies; 
d. develop innovative diagnostics data networks for community settings to monitor 
status and spread of anti-microbial resistance; and 
e. Study the role of existing and new business models (start-ups and small-medium 
enterprises) in assisting innovation through public-private partnership. 
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